Lymphoma Hodgkin Y Linked Pseudoautosomal C1839076
Y-linked pseudoautosomal Hodgkin lymphoma is an exceptionally rare genetic form of Hodgkin lymphoma. It involves genetic changes on the sex chromosomes and requires careful diagnosis and treatment planning. Patients receive Hodgkin lymphoma treatment regimens adapted to their specific genetic condition.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Painless lymphadenopathy
(oncologic)Fever
(oncologic)Night sweats
(oncologic)Fatigue
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Chemotherapy regimen
Combination chemotherapy using standard protocols such as ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) to target and destroy malignant Hodgkin lymphoma cells throughout the lymphatic system.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Radiation therapy
Targeted radiation therapy to affected lymph node regions, typically administered after chemotherapy to eliminate residual malignant cells and reduce recurrence risk.
Additional treatment options
Immunotherapy with checkpoint inhibitors
Monoclonal antibody therapy targeting PD-1 or PD-L1 to enhance the immune system's ability to recognize and destroy Hodgkin lymphoma cells, particularly useful in refractory cases.
medicationStem cell transplantation
High-dose chemotherapy followed by autologous or allogeneic stem cell rescue to restore bone marrow function after intensive treatment for relapsed or refractory disease.
surgicalSurveillance imaging and labs
Regular PET-CT scans and laboratory tests to detect disease recurrence early, typically performed every 3-6 months for the first 2 years following treatment completion.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Lymphoma Hodgkin Y Linked Pseudoautosomal C1839076?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Lymphoma Hodgkin Y Linked Pseudoautosomal C1839076. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy